Literature DB >> 6285713

Neonatal acyclovir pharmacokinetics in patients with herpes virus infections.

M Hintz, J D Connor, S A Spector, M R Blum, R E Keeney, A S Yeager.   

Abstract

A preliminary analysis is presented of the pharmacokinetics of acyclovir in neonatal patients with herpes simplex virus infections. Mean peak acyclovir levels (microM +/- SD) at 5, 10, and 15 mg/kg per dose were 30.0 +/- 9.9, 61.2 +/- 18.3, and 86.1 +/- 23.5, with corresponding mean trough levels (microM +/- SD) of 5.3 +/- 3.4, 10.1 +/- 8.4, and 13.8 +/- 11.1, respectively. The mean half-life (t 1/2 beta) of acyclovir was 3.78 +/- 1.21 hours. The mean percent urinary recovery of acyclovir (+/- SD) at each dosage level was similar, with an overall mean recovery of 65 percent. The mean acyclovir concentration in urine did not exceed the solubility of acyclovir in bladder urine (1,300 micrograms/ml). Generally, neonatal acyclovir pharmacokinetics was consistent with previous reports from studies of adults.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285713     DOI: 10.1016/0002-9343(82)90093-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

1.  Pharmacokinetics of acyclovir suspension in infants and children.

Authors:  W M Sullender; A M Arvin; P S Diaz; J D Connor; R Straube; W Dankner; M J Levin; S Weller; M R Blum; S Chapman
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

2.  Use and safety of antimicrobial agents during pregnancy.

Authors:  A W Chow; P J Jewesson
Journal:  West J Med       Date:  1987-06

Review 3.  Clinical pharmacokinetics of acyclovir.

Authors:  O L Laskin
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

4.  Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis.

Authors:  M Tod; F Lokiec; R Bidault; F De Bony; O Petitjean; Y Aujard
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 5.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 6.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 7.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

Review 8.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

9.  Population pharmacokinetics of intravenous acyclovir in preterm and term infants.

Authors:  Mario R Sampson; Barry T Bloom; Robert W Lenfestey; Barrie Harper; Angela D Kashuba; Ravinder Anand; Daniel K Benjamin; Edmund Capparelli; Michael Cohen-Wolkowiez; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 3.806

10.  Acyclovir suppression to prevent recurrent genital herpes at delivery.

Authors:  L L Scott; L M Hollier; D McIntire; P J Sanchez; G L Jackson; G D Wendel
Journal:  Infect Dis Obstet Gynecol       Date:  2002
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.